35Pharma key facts
- Operator of a biopharmaceutical company intended for pulmonary hypertension and musculoskeletal disorders.
- 35Pharma’s last known valuation is $950.0M (Apr 2026).
- It has raised $70.0M; the latest was Merger/Acquisition ($950.0M) in Apr 2026.
- Notable investors include Logos Capital, Frazier Healthcare Partners, Marshall Wace, Vivo Capital, Surveyor Capital — 10 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watch 35Pharma: the Monday email on marks, rounds and moves
35Pharma funding rounds
No funding rounds for 35Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
35Pharma valuation
35Pharma's last known valuation is $950 million, from Apr 2026. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
35Pharma investors
10 investors are on record for 35Pharma, including Logos Capital, Frazier Healthcare Partners, Marshall Wace and Vivo Capital. By type, the record holds 4 venture capital firms, 4 hedge funds and 1 asset manager.
About 35Pharma
Operator of a biopharmaceutical company intended for pulmonary hypertension and musculoskeletal disorders. The company combines protein engineering expertise with a deep understanding of transforming growth factor-beta structure-function relationships to design potent ligand traps for cardiovascular and metabolic diseases, enabling scientists to develop biologics for treating patients.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2021
- Employees
- 45
- Website
- 35pharma.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
35Pharma’s last known valuation, Apr 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.